Defining the circulating genome of high-risk plasma cell disorders to improve risk stratification and clinical management

Dr Mithraprabhu and her team aims to overcome the challenges caused by the genetic complexity of multiple myeloma by usi...

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy

The team has developed a methodology to map the fibrotic tumour landscape, through real-time imaging of (i) the proximit...

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Associate Professor MacKenzie and her team will define specific drug targets and develop diagnostic methods for therapeu...

Exploiting a new epigenetic regulatory mechanism for sustaining leukaemia-initiating activity

Dr Jenny Wang and her team have discovered a key self-renewal pathway essential for the survival of leukaemia-initiating...

Pan-cancer Assessment of Sensitivity Towards Novel Selective Oncogenic JNK Inhibitors

Dr Latham’s team is pursuing the preclinical assessment and development of a novel class of drugs that aim to prevent ...

Resolving Prostate Cancer: Elucidating the epigenetics of tumour microenvironment

Dr Pidsley’s research will lead to the development of a novel sensitive epigenetic test, to accurately determine tumou...

Load more